ARTICLE | Politics, Policy & Law
The company’s proposed rebate plan is broader in scope than that of J&J
By Richard Guy, Biopharma Analyst
November 16, 2024 1:42 AM UTC
The pharmaceutical industry, exasperated with the federal government, is seeking relief in the courts from ever-expanding 340B costs.
Last week, Johnson & Johnson (NYSE:JNJ) filed a lawsuit to shield from the Health Resources and Services Administration (HRSA) its proposal to pay rebates to certain 340B entities purchasing Stelara ustekinumab and Xarelto rivaroxaban, instead of extend discounts. Now, Eli Lilly and Co. (NYSE:LLY) has filed a separate suit over its proposal to pay rebates to covered entities. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654222/lilly-sues-for-the-right-to-rebate-all-its-products-under-340b